HOME >> MEDICINE >> NEWS
Maxim Phase II Clinical Trial Highlights Substantial Increase In Leukemia-FreeSurvival For Acute Myelogenous Leukemia Patients

Clinical Results Will Be Presented Today at 1998 American Society of Hematology (ASH) Conference

San Diego, CA, December 7, 1998 - Maxim Pharmaceuticals (AMEX: MMP, SSE: MAXM) announced updated results from an ongoing Phase II clinical trial of its lead drug Maxamine® in patients with acute myelogenous leukemia (AML). The results from the trial suggest encouraging increases in leukemia-free survival in AML patients treated in remission with Maxamine Therapy.

The updated results will be presented today by Mats Brune, M.D., and Elisabeth Wallhult, R.N., Department of Hematology, Sahlgrenska University Hospital, Gothenburg, Sweden, at the American Society of Hematology Conference in Miami, Florida. "We are very pleased with the number of patients that remain in leukemia-free remission," said Dr. Brune.

The strength of the Phase II data led Maxim to commence a Phase III clinical trial of Maxamine as a remission therapy for AML patients. The Phase III trial, which began earlier this year, is underway in 11 countries and more than 100 clinical sites around the world. "The number of clinical sites that have approached Maxim and agreed to participate in this trial has greatly exceeded our expectations," said Dr. Kurt Gehlsen, chief technical officer of Maxim. "We believe that this interest results from the promising data we have seen in the Phase II trial for this population of patients who have limited options for therapy today."

Background on AML

AML is the most common form of acute leukemia in adults, and prospects for long-term survival are poor for the majority of patients. There are approximately 20,000 new cases and 15,000 deaths caused by AML each year in the United States, Europe and Australia.

Once diagnosed with AML, patients are typically treated with chemotherapy, and the majority achieve complete remission ("CR"). Unfortunately 75-80% of patients who achieve their first CR ("CR1") will relapse, and the medi
'"/>

Contact: Amy Flood
a.flood@noonanrusso.com
415-677-4455 x211
Noonan/Russo Communications
7-Dec-1998


Page: 1 2 3 4 5 6

Related medicine news :

1. Elan and Biogen Idec announce results from Phase III maintenance trial of Antegren
2. Phase II trial of anthrax vaccine to begin
3. NIAID Phase III HIV vaccine trial to determine correlates of protection will not proceed
4. MetaPhore Pharmaceuticals initiates Phase I clinical trial of enzyme mimetic compound for oncology
5. Maret Pharmaceuticals presents promising Phase I/II clinical MARstem™ results at international symposium on new drugs in cancer therapy
6. Penn researchers announce results of Phase I trial using combretastatin drug
7. Anti-cocaine vaccine produces antibodies and is shown to be safe in Phase 1 study conducted by Yale researcher
8. Results of NUVANCE (IL-4 receptor) in Phase I/II study in asthma patients featured at AAAAI Late-Breaker Abstract and Asthma Therapy Sessions
9. ILEX Oncology & LeukoSite report results from pivotal Phase II CAMPATH (R) trial; Results suggest new hope for refractory chronic lymphocytic leukemia
10. Abgenix Reports Positive Survival Data From A Phase II Trial Of ABX-CBL In Graft Versus Host Disease
11. Immunex Advances CD40 Ligand To Phase II Clinical Trial In People With Metastatic Kidney Cancer

Post Your Comments:
*Name:
*Comment:
*Email:


(Date:8/31/2020)... ... August 31, 2020 , ... In an effort to give back to ... 10 percent of each hotel room booked with a special new rate code to ... Indiana (RMHC-CNI) , effective immediately. Donations will be applied to any room type, ...
(Date:8/31/2020)... (PRWEB) , ... August 31, 2020 , ... ... intended to improve outcomes for patients with advanced heart failure, today announced that ... grant in the amount of $555,358 from the National Heart, Lung, and Blood ...
(Date:8/28/2020)... ... August 28, 2020 , ... Ernst & Young ... named an Entrepreneur Of The Year® 2020 Florida Award finalist. Now in its ... ambitions deliver innovation, growth and prosperity as they build and sustain successful businesses ...
(Date:8/28/2020)... ... 28, 2020 , ... The 15 scholarships being offered by ... Wellness mobile app and web-portal. NCPCV received a 2020 grant from Motorola Solutions ... year to organizations, such as Destination Imagination, which support and advance public safety ...
(Date:8/28/2020)... ... August 28, 2020 , ... Integrated Viral Protection (IVP Air) today ... to deploy its breakthrough Mobile Biodefense Indoor Air Protection System that is the first ... plans to fully reopen equipped with the filtration system on September 8th. , ...
Breaking Medicine News(10 mins):
(Date:8/26/2020)... ... August 26, 2020 , ... ... Testing division, expands its technology footprint with the addition of Novocyte Quanteon™ ... With industry-leading biomarker solutions, complemented with traditional ligand-binding assays and study management ...
(Date:8/26/2020)... (PRWEB) , ... August 26, ... ... Holdings company today announced that it has entered into definitive agreement to ... CME/CE, primarily focused on pharmacists and pharmacy technicians. , CEA represents ...
(Date:8/26/2020)... ... August 26, 2020 , ... Crossroads Hospice ... added CHC and CPCO to her name. , That’s thanks to her completion ... and the Certified Professional Compliance Officer (CPCO.) , The CHC is designed to ...
Breaking Medicine Technology:
Cached News: